Pharma Reaserch Prod Co Ltd Working Capital to Net Assets Ratio
Pharma Reaserch Prod Co Ltd working capital to net assets ratio. Pharma Reaserch Prod Co Ltd (214450) has a Working Capital to Net Assets ratio of 89.7% as of December 2025. Working capital of ₩649.07 Billion (current assets of ₩759.54 Billion minus current liabilities of ₩110.47 Billion) is measured against net assets of ₩723.88 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 214450 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Pharma Reaserch Prod Co Ltd (2015–2025)
Working capital to net assets ratio of Pharma Reaserch Prod Co Ltd from 2015 to 2025. This chart shows how Pharma Reaserch Prod Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2015 to 2025. As of December 2025, the ratio stands at 89.7%, reflecting working capital of ₩649.07 Billion against net assets of ₩723.88 Billion KRW. See Pharma Reaserch Prod Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Pharma Reaserch Prod Co Ltd Working Capital to Net Assets Ratio by Year (2015–2025)
Pharma Reaserch Prod Co Ltd working capital to net assets ratio by year from 2015 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Pharma Reaserch Prod Co Ltd from 2015 to 2025, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 214450 total assets.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 89.7% | ₩649.07 Billion | ₩723.88 Billion | ₩759.54 Billion | ₩110.47 Billion | ▲ +6.8 pp |
| 2024 | 82.8% | ₩471.72 Billion | ₩569.44 Billion | ₩554.54 Billion | ₩82.82 Billion | ▲ +41.6 pp |
| 2023 | 41.2% | ₩190.57 Billion | ₩462.19 Billion | ₩256.47 Billion | ₩65.90 Billion | ▼ -15.0 pp |
| 2022 | 56.2% | ₩193.09 Billion | ₩343.50 Billion | ₩247.34 Billion | ₩54.25 Billion | ▲ +4.2 pp |
| 2021 | 52.0% | ₩158.79 Billion | ₩305.44 Billion | ₩206.79 Billion | ₩48.01 Billion | ▲ +14.7 pp |
| 2020 | 37.3% | ₩91.55 Billion | ₩245.42 Billion | ₩127.40 Billion | ₩35.85 Billion | ▼ -3.8 pp |
| 2019 | 41.1% | ₩85.88 Billion | ₩209.07 Billion | ₩104.47 Billion | ₩18.59 Billion | ▼ -4.6 pp |
| 2018 | 45.7% | ₩90.29 Billion | ₩197.62 Billion | ₩105.77 Billion | ₩15.48 Billion | ▼ -13.3 pp |
| 2017 | 59.0% | ₩105.47 Billion | ₩178.85 Billion | ₩112.34 Billion | ₩6.86 Billion | ▼ -11.1 pp |
| 2016 | 70.1% | ₩120.26 Billion | ₩171.64 Billion | ₩126.47 Billion | ₩6.21 Billion | ▼ -11.0 pp |
| 2015 | 81.1% | ₩127.06 Billion | ₩156.75 Billion | ₩134.21 Billion | ₩7.16 Billion | — |